Gastric
and Esophageal Cancer Drugs Market, by Therapy Type (Chemotherapy, Targeted
Therapy, and Immunotherapy), by Disease Condition (Adenocarcinomas,
Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous Cell Carcinoma, and
Others), by Distribution Channel (Hospital, Retail Pharmacy, and Online
Pharmacy), and by Geography (North America, Europe, Asia Pacific, Latin
America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity
Analysis 2018 – 2026
Gastric and esophageal cancers
are characterized by growth of malignant (cancerous) cells, forming a tumor,
within the lining of stomach and esophagus. Smoking, excessive alcohol
consumption, and Barrett’s esophagus can causes gastric and esophageal cancers.
Symptoms of gastric and esophageal cancers include difficulty in swallowing
(dysphagia), weight loss, chest pain, indigestion or heartburn, coughing or
hoarseness, pain behind the breastbone. Early stage of gastric and esophageal
cancer does not show any of this signs and symptoms.
Gastric and Esophageal Cancer
Drugs Market- Drivers
Increasing number of cancer drugs
in pipeline studies and rising involvement of key players for development of
cancer treatment are expected to propel gastric and esophageal cancer drugs
market growth. For instance, in April 2016, Centre Hospitalier Universitaire de
Besancon, initiated Phase 1 and Phase 2 clinical trial for Carboplatin to
determine the maximum tolerated dose (MTD) and recommended doses for phase II
(RP2D) by considering the treatment scheme of Dutch study for chemotherapy and
radiotherapy. The study is conducted in elderly patients with esophagus cancer.
Carboplatin is an anticancer chemotherapy drug from alkylating agent category.
The study is estimated to complete by April 2024.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2438
Moreover, in February 2017, Henan
Cancer Hospital in collaboration with Jiangsu HengRui Medicine Co., Ltd.,
initiated Phase 2 exploratory clinical trial to evaluate the efficacy of
Apatinib, treatment for advanced esophagus cancer. Apatinib is a tyrosine kinase
inhibitor that selectively inhibits the vascular endothelial growth factor
receptor-2(VEGFR2).
However, high cost of therapy for
the treatment of gastric and esophageal cancers is expected to restraint the
market growth. For instance, as per the report published in Healthday, in 2013,
cancer patients paid US$ 207,000 a year for the treatment and medications while
in 1995 the cost was US$ 54,100 a year.
Gastric and Esophageal Cancer Drugs
Market- Regional Analysis
On the basis of region, the
global gastric and esophageal cancer drugs market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Geographically, North America is
expected to be the leading region in the gastric and esophageal cancer drugs
market during the forecast period, owing to high prevalence of esophageal
cancer in this region. For instance, the American Cancer Society’s estimated
that about 17,650 new esophageal cancer cases in the U.S. will be diagnosed
(13,750 in men and 3,900 in women) by 2019. Moreover, mergers and acquisitions
activities by key players in this region are expected to propel the market
growth during the forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/gastric-and-esophageal-cancer-drugs-market-2438
For instance, in December 2018,
GlaxoSmithKline plc announced the acquisition of TESARO Inc, an oncology
focused company based in Massachusetts, U.S. This acquisition is expected to
strengthen GSK’s pharmaceutical business by accelerating GSK’s pipeline and commercial
capability in oncology.
Key players in Europe are focused
on various business strategies such as acquisitions and mergers, which in turn
boosts growth of the market. For instance, in September 2018, Boehringer
Ingelheim acquired all shares of ViraTherapeutics, an Austria-based
biopharmaceutical company, specializing in the development of oncolytic viral
therapies. The total transaction value for this acquisition was US$ 240.52
million. This acquisition strengthened Boehringer Ingelheim’s commitment to
research and development for viral-based immuno-oncology treatment.
Key players for gastric and
esophageal cancer drugs market includes Amgen, Eli Lilly and Company, F.
Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH,
Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson,
Gilead Sciences, Merck & Co. and others.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2438
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment